Abstract
Risperidone is the first new generation antipsychotic drug to become available as a long-acting injection (LAI). The purpose of this study was to evaluate the effects of switching from oral risperidone to risperidone LAI (RLAI) on cognitive function in stable schizophrenia patients compared with the effects of continuing oral risperidone. Sixteen stable patients who had received risperidone monotherapy for at least 3 months were enrolled (the RLAI group). Before and 24 weeks after switching to RLAI, the Japanese-language version of the Brief Assessment of Cognition in Schizophrenia (BACS-J) and the Positive and Negative Syndrome Scale (PANSS) were administered. To exclude the possibility of learning effects on the BACS-J results, 14 patients with stable schizophrenia who continued oral risperidone treatment were also assessed (the RIS group). The two groups did not differ with respect to changes in the PANSS score, and no emergent side effects, including extrapyramidal symptoms, were observed. The BACS-J score for verbal memory exhibited greater improvement in the RLAI group than in the RIS group (p = 0.047). The results of this preliminary study suggest that switching from oral risperidone to RLAI may improve verbal capability more than continuing with oral risperidone. However, these findings must be replicated in a larger, double-blind study.
Highlights
Schizophrenia is a chronic disease with an intermittent course and numerous relapses over time [1]
Treatments that are deliverable as long-acting injections (LAIs) are among the more useful therapies in clinical settings
We evaluated the effects of switching from oral risperidone to risperidone LAI (RLAI) on cognitive function in stable schizophrenia patients compared with the effects of continuing oral risperidone
Summary
Schizophrenia is a chronic disease with an intermittent course and numerous relapses over time [1]. Relapses of schizophrenia are known to adversely affect many biosocial factors [2], and antipsychotic treatment is pivotal for preventing relapse [3]. Patients with schizophrenia adherence is often worse and difficult to prevent relapse [4], which greatly impacts the risk of relapse [5]. Risperidone is one of the most widely used atypical antipsychotic drugs for acute schizophrenia treatment. We always continue with maintenance phase treatment after acute phase treatment. Most patients experience relapse because of low medication adherence, high stress levels, and problems with the use of alcohol and/or drugs. Treatments that are deliverable as long-acting injections (LAIs) are among the more useful therapies in clinical settings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
